Table 3.
Summary of selected ongoing clinical trials evaluating molecular therapies in pancreatic ductal adenocarcinoma (according to www.clinicalTrials.gov, accessed July 2015)
| Category | Clinical trial number | PDA setting | Medications studied | Phase | Status | Estimated completion |
| Tumor suppressor genes | ||||||
| NCT01585805 | Locally advanced/metastatic | Gem and Cisplatin ± Veliparib vs Veliparib alone | II | Recruiting | 07/2017 | |
| NCT01296763 | Advanced | Irinotecan + Cisplatin + Mitomycin C ± Olaparib | I/II | Ongoing, not recruiting | 01/2014 | |
| Recombinant hyaluronidase | ||||||
| NCT01959139 | Metastatic | FOLFIRINOX ± PEGPH20 | I/II | Recruiting | 12/2017 | |
| NCT01839487 | Metastatic | Gem + Nab-paclitaxel vs Gem + Nab-paclitaxel + PEGPH20 | II | Recruiting | 04/2016 | |
| Vaccine therapy | ||||||
| NCT02004262 | Metastatic | Cy + GVAX + CRS-207 vs Chemotherapy vs CRS-207 | II | Recruiting | 12/2016 | |
| NCT01072981 | Adjuvant | Chemotherapy vs Chemo-radiotherapy ± Algenpantucel-L | III | Ongoing, not recruiting | 06/2016 | |
| NCT01836432 | Neoadjuvant | FOLFIRINOX ± Algenpantucel-L | III | Recruiting | 09/2015 | |
| Immune checkpoint | NCT02472977 | Metastatic | Ulocuplumab (CXCR4) and nivolumab (PD1) | IB | Recruiting | 7/2017 |
| CAR-T cell therapy | ||||||
| NCT01897415 | Metastatic | Autologous redirected RNA mesothelin specific CAR-T cells | I | Not recruiting | 01/2015 | |
| NCT01583686 | Metastatic | CAR-T cell receptor | I/II | Recruiting | 12/2018 | |
| Micro-RNA-21 targeted therapy | ||||||
| NCT01274455 | Locally advanced | Gem + Plasmid DNA CYL-02 | I | Not recruiting | 12/2013 | |
| Signal transduction inhibitors | ||||||
| Janus kinase targeted | NCT02119663 | Locally advanced/metastatic | Capecitabine + Ruxolitinib vs Capecitabine + Placebo | III | Recruiting | 06/2017 |
| NCT02117479 | Locally advanced/metastatic | Capecitabine + Ruxolitinib vs Capecitabine + Placebo | III | Recruiting | 12/2015 | |
| Wnt targeted | NCT02050178 | Metastatic | OMP-54F28 + Gem-Nab-paclitaxel | I | Recruiting | 12/2016 |
| NCT01764477 | Metastatic | PRI-724 + Gem | I | Recruiting | 03/2016 | |
| Notch inhibitor | NCT01647828 | Locally advanced/metastatic | OMP-59R5 + Gem-Nab-paclitaxel | I/II | Recruiting | 01/2016 |
| TGF-β inhibitor | NCT01373164 | Locally advanced/metastatic | LY2157299 + Gem | I/II | Not recruiting | 11/2015 |
PDA: Pancreas ductal adenocarcinoma; Gem: Gemcitabine; FOLFIRINOX: 5-fluorouracil, leucovorin, irinotecan, oxaliplatin; CAR-T: Chimeric antigen receptor T cell; TGF-β: Transforming growth factor-β; Cy: Cyclophosphamide.